US suitor wins Shire, and a British tax rate, in fifth takeover approach

The deal as it stands – £24.44 in cash and 0.896 AbbVie shares – would give Shire’s investors a 25 per cent stake in the combined company

Shire finally succumbed to US suitor AbbVie at the fifth time of asking yesterday as the drug group’s board said it was ready to recommend an improved $53bn (£31bn) takeover.

The FTSE 100 big-pharma player, best-known for its Vyvanse blockbuster treatment for attention deficit hyperactivity disorder, has been in the sights of AbbVie since early May when the US firm tabled its first bid proposal.

The two boards are now locked in “detailed discussions” in New York following the improved £53.20-a-share proposal, but AbbVie looks to have succeeded where US rival Pfizer failed in its much bigger £63bn bid for AstraZeneca. The deal as it stands – £24.44 in cash and 0.896 AbbVie shares – would give Shire’s investors a 25 per cent stake in the combined company. The shares rose 33p to 4,903p.

The company said: “The board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the revised proposal to Shire shareholders. Accordingly, the board is in detailed discussions with AbbVie in relation to these terms.”

The pursuit of Shire has stoked far less controversy than AstraZeneca because – apart from offices in Basingstoke – it is headquartered in Dublin but managed from Boston. The vast majority of Shire’s staff and sales are in the US.

AbbVie covets Shire’s rare diseases unit, bolstered by the $4.2bn deal for the US company ViroPharma last year, which the company is building up in response to more generic competitors to its ADHD drugs. It also wants Shire’s portfolio to reduce its reliance on its top-selling rheumatoid arthritis drug Humira, which accounts for 60 per cent of its sales but loses US patent protection in late 2016.

AbbVie is also looking to cut its US tax bill by moving its tax base to Britain, in a tactic known as inversion. Mick Cooper, an analyst at Edison Investment Research, said: “The proposed offer seems a fair price that represents good value for both companies’ shareholders.”

Shire previously fought to maintain its independence as its chairman Susan Kilsby unveiled a new target to double annual product sales, which account for the bulk of revenues, to $10bn by 2020.

The company was founded in 1986, with early successes including a range of calcium products to treat osteoporosis, and listed in 1996. The US firm was formed last year when Abbott Laboratories split into two companies, a medical products business which retained the Abbott name and a pharmaceuticals firm which became AbbVie.

Hooked: the string of deals

AbbVie’s £31bn takeover of Shire is the latest in a string  of huge deals – both successful and unsuccessful – in the sector this year:

April: Britain’s top drug maker, GlaxoSmithKline, reshuffles its drug cabinet with a three-part, multi-billion dollar asset swap with Swiss rival Novartis. It sells cancer drugs for Brentford-based Glaxo for up to $16bn, buying the Swiss giant’s vaccines operation for $5.25bn while the consumer health divisions of both are merged.

April-May: US firm Pfizer launches a takeover attempt for AstraZeneca – eventually raising its proposal to a potential $118bn or £55 a share – but the offer isn’t enough to bring Astra’s board to the table. Bad-tempered negotiations are conducted against a backdrop of political concerns over the impact of a deal on the UK’s research and development capacity.

April-July: Botox maker Allergan is still fending off a $53bn hostile approach from Canadian drug company Valeant and activist investor William Ackman.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45,000: SThree: SThree Group have been well e...

Ashdown Group: IT Manager / Development Manager - NW London - £58k + 15% bonus

£50000 - £667000 per annum + excellent benefits : Ashdown Group: IT Manager / ...

Recruitment Genius: Sales Consultant / Telemarketer - OTE £20,000

£13000 - £20000 per annum: Recruitment Genius: Scotland's leading life insuran...

Ashdown Group: Training Programme Manager - City, London

£40000 - £45000 per annum + benefits : Ashdown Group: Training Programme Manag...

Day In a Page

Where the spooks get their coffee fix: The busiest Starbucks in the US is also the most secretive

The secret CIA Starbucks

The coffee shop is deep inside the agency's forested Virginia compound
Revealed: How the Establishment closed ranks over fallout from Loch Ness Monster 'sighting'

How the Establishment closed ranks over fallout from Nessie 'sighting'

The Natural History Museum's chief scientist was dismissed for declaring he had found the monster
One million Britons using food banks, according to Trussell Trust

One million Britons using food banks

Huge surge in number of families dependent on emergency food aid
Excavation at Italian cafe to fix rising damp unearths 2,500 years of history in 3,000 amazing objects

2,500 years of history in 3,000 amazing objects

Excavation at Italian cafe to fix rising damp unearths trove
The Hubble Space Telescope's amazing journey, 25 years on

The Hubble Space Telescope's amazing journey 25 years on

The space telescope was seen as a costly flop on its first release
Did Conservative peer Lord Ashcroft quit the House of Lords to become a non-dom?

Did Lord Ashcroft quit the House of Lords to become a non-dom?

A document seen by The Independent shows that a week after he resigned from the Lords he sold 350,000 shares in an American company - netting him $11.2m
Apple's ethnic emojis are being used to make racist comments on social media

Ethnic emojis used in racist comments

They were intended to promote harmony, but have achieved the opposite
Sir Kenneth Branagh interview: 'My bones are in the theatre'

Sir Kenneth Branagh: 'My bones are in the theatre'

The actor-turned-director’s new company will stage five plays from October – including works by Shakespeare and John Osborne
The sloth is now the face (and furry body) of three big advertising campaigns

The sloth is the face of three ad campaigns

Priya Elan discovers why slow and sleepy wins the race for brands in need of a new image
How to run a restaurant: As two newbies discovered, there's more to it than good food

How to run a restaurant

As two newbies discovered, there's more to it than good food
Record Store Day: Remembering an era when buying and selling discs were labours of love

Record Store Day: The vinyl countdown

For Lois Pryce, working in a record shop was a dream job - until the bean counters ruined it
Usher, Mary J Blige and Will.i.am to give free concert as part of the Global Poverty Project

Mary J Blige and Will.i.am to give free concert

The concert in Washington is part of the Global Citizen project, which aims to encourage young people to donate to charity
10 best tote bags

Accessorise with a stylish shopper this spring: 10 best tote bags

We find carriers with room for all your essentials (and a bit more)
Paul Scholes column: I hear Manchester City are closing on Pep Guardiola for next summer – but I'd also love to see Jürgen Klopp managing in England

Paul Scholes column

I hear Manchester City are closing on Pep Guardiola for next summer – but I'd also love to see Jürgen Klopp managing in England
Jessica Ennis-Hill: 'I just want to give it my best shot'

Jessica Ennis-Hill: 'I just want to give it my best shot'

The heptathlete has gone from the toast of the nation to being a sleep-deprived mum - but she’s ready to compete again. She just doesn't know how well she'll do...